HE4 与 CA125 联合检测在妇科肿瘤诊断中的作用评价

Evaluation of the Role of HE4 and CA125 Combination Test in the Diagnosis of Gynecological Tumors

摘要:

〔摘 要〕 目的：对人附睾蛋白 4（HE4）与糖类抗原 125（CA125）联合检测在妇科肿瘤诊断中的应用效果进行评价。 方法： 选取 2021 年 12 月至 2022 年 12 月间梅州市梅县区中医医院收治的 68 例妇科肿瘤患者为研究对象，经病理检查确诊 恶性肿瘤 32 例，良性肿瘤 36 例，另选取同期来梅州市梅县区中医医院健康体检的女性 45 例作为对照，检测所有研究对象 的血清 HE4 与 CA125 水平，分析血清 HE4 与 CA125 在妇科肿瘤诊断中的使用价值，以及在妇科肿瘤良恶性鉴别中的诊断 价值。 结果：恶性肿瘤患者的血清 HE4、CA125 水平均高于良性肿瘤患者与健康体检女性，且良性肿瘤患者均高于健康体检 女性，差异均具有统计学意义（P ＜ 0.05）。良、恶性肿瘤患者的 HE4、CA125 单一及联合检测的阳性率均高于健康体检女性， 差异均具有统计学意义（P ＜ 0.05）；良、恶性肿瘤患者的 CA125 阳性率比较，差异无统计学意义（P ＞ 0.05）；恶性 肿瘤患者的 HE4、联合检测阳性率均高于良性肿瘤患者比较，差异均具有统计学意义（P ＜ 0.05）。 结论：血清 HE4 对妇 科肿瘤的诊断灵敏度相对 CA125 更高，两者联合检测有助于提升肿瘤诊断的阳性率，并可实现对肿瘤良恶性的进一步鉴别。

Abstract:

〔Abstract〕 Objective To evaluate the effectiveness of combining human eididymis 4 (HE4) and Carbohydrate antigen 125 (CA125) in the diagnosis of gynecological tumors. Methods A total of 68 gynecological tumor patients admitted to Meizhou District Meixian Hospital of Traditional Chinese Medicine from December 2021 to December 2022 were selected as the research subjects. 32 cases of malignant tumors and 36 cases of benign tumors were confirmed through pathological examination, and 45 women who came to Meizhou District Meixian Hospital of Traditional Chinese Medicine for health examination during the same period were selected as the control. The value of serum HE4 and CA125 in the diagnosis of gynecological tumors was analyzed, and their diagnostic value in differentiating between benign and malignant gynecological tumors was determined. Results The levels of serum HE4 and CA125 in patients with malignant tumors were higher than those in patients with benign tumors and women with healthy examination, and the levels of serum HE4 and CA125 in patients with benign tumors were higher than those in women with healthy examination, and the differences were statistically significant (P < 0.05). The positive rates of HE4 and CA125 of single and combined tests in benign and malignant tumors were higher than those in women with healthy examination, and the differences were statistically significant (P < 0.05); there was no statistically significant difference of the positive rate of CA125 between patients with benign and malignant tumors (P > 0.05), the positive rates of HE4 and combined tests of pateints with malignant tumors were higher than those of patients with benign tumors, and the differences were statistically significant (P <0.05). Conclusion The diagnostic sensitivity of serum HE4 for gynecological tumors is higher than that of CA125, and the combination of the two tests can help to improve the positive rate of tumor diagnosis and realize the further differentiation of benign and malignant tumors.